By Fineline Cube 
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic partnership with domestic biotech firm InxMed Limited, securing exclusive marketing, promotion, and omni-channel commercialization rights in China for two focal adhesion kinase (FAK) inhibitors: ifebemtinib (IN10018) and IN10028. Financial terms of the agreement were not disclosed.
Drug Development Status
| Compound | Development Stage | Regulatory Designations | Key Features |
|---|---|---|---|
| IN10018 (ifebemtinib) | Phase III trials in China | • 3 Breakthrough Therapy Designations (NMPA) • 1 Fast Track Designation (FDA) | Dual regulation of kinase catalysis and protein scaffolding |
| IN10028 | Phase I study pending (NMPA approved) | None disclosed | Second-generation FAK inhibitor with improved PK properties and safety profile |
Therapeutic Applications
Both compounds are being developed for the treatment of multiple solid tumors, including:
- Platinum-resistant ovarian cancer
- Non-small cell lung cancer (NSCLC)
- Pancreatic cancer
IN10028 builds upon the foundation of first-generation FAK inhibitors, maintaining excellent anti-tumor activity while achieving further improvements in pharmacokinetic properties and safety characteristics.
Strategic Partnership Context
- Market Opportunity: China’s solid tumor market represents one of the largest oncology segments globally, with significant unmet needs in platinum-resistant ovarian cancer and pancreatic cancer
- Commercial Strategy: Fosun Pharma’s extensive hospital network and omni-channel capabilities position it to rapidly scale distribution upon potential approval
- Competitive Landscape: FAK inhibitors represent an emerging class of targeted therapies with potential to address resistance mechanisms in difficult-to-treat solid tumors
- R&D Synergy: The partnership leverages InxMed’s innovative drug discovery platform with Fosun’s commercial infrastructure and regulatory expertise
This collaboration strengthens Fosun’s oncology portfolio and provides InxMed with a well-capitalized partner to maximize the commercial potential of its FAK inhibitor pipeline in the Chinese market.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech